Alloderm与Dermacell在即刻异体乳房重建中患者报告结局比较:一项随机对照试验
该单中心开放标签随机对照试验将62例接受即刻异体乳房重建的患者随机分入Alloderm组或Dermacell组,使用BREAST-Q评估患者报告结局。术后3个月Alloderm组在乳房满意度、整体结果满意度、外科医生满意度及信息满意度方面显著优于Dermacell组,但术后12个月两组无统计学显著差异。
要点
- 术后3个月Alloderm组乳房满意度(67 vs 53, p=0.03)及整体结果满意度(85 vs 61, p=0.003)显著更高。
- 术后3个月Alloderm组外科医生满意度(89 vs 67, p=0.01)及信息满意度(74 vs 59, p=0.02)显著更高。
- 术后12个月两组患者报告结局无统计学显著差异(p>0.05)。
核心结论
- 短期分析支持使用Alloderm,但长期来看两种产品在患者报告结局上无明显差异。
研究设计与样本
- 单中心、开放标签、随机对照试验,纳入接受即刻异体乳房重建的乳腺癌或乳腺癌预防患者。
- Alloderm组23例(74%)、Dermacell组27例(87%)完成BREAST-Q问卷。
- 采用线性混合模型分析BREAST-Q随时间的变化。
主要发现
- 基线时两组在乳房满意度、心理社会福祉、性福祉及身体福祉方面的BREAST-Q评分相似(p>0.05)。
- 术后3个月Alloderm组乳房满意度为67 vs 53(p=0.03)。
- 术后3个月Alloderm组整体结果满意度为85 vs 61(p=0.003)。
- 术后3个月Alloderm组外科医生满意度为89 vs 67(p=0.01),信息满意度为74 vs 59(p=0.02)。
- 术后12个月两组患者报告结局无统计学显著差异(p>0.05)。
临床怎么用
- 在即刻异体乳房重建中,若关注术后短期患者满意度,可优先考虑Alloderm。
- 长期患者报告结局两种产品无显著差异,选择时可综合考量其他因素。
局限性
- 单中心研究,样本量较小(共62例随机),问卷完成率在Alloderm组为74%、Dermacell组为87%。
- 开放标签设计,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alloderm and Dermacell are the two leading human acellular dermal matrices (ADM) in immediate breast reconstruction (IBR). Despite differences in sterility, consistency, thickness and cost, there are no comparative trials to date to compare patient-reported outcome measures (PROM) between the two products. The purpose of this study was to determine if there was a difference in patient-reported outcomes (as measured by the BREAST-Q) between patients reconstructed with Alloderm and Dermacell. METHODS: A single center, open-label, randomized control trial of patients undergoing IBR with an implant for breast cancer or breast cancer prophylaxis was performed. Patients were randomized to either Alloderm or Dermacell. Baseline demographic data were compared, and linear mixed models were used to identify associations with BREAST-Q over time. RESULTS: Between June 2016 and October 2018, 62 patients were randomized into two groups, 31(50%) Alloderm and 31(50%) Dermacell. Of these, 23(74%) patients in the Alloderm group and 27(87%) patients of the Dermacell group filled out BREAST-Q questionnaires. Baseline BREAST-Q scores with respect to satisfaction with breasts, psychosocial well-being, sexual well-being, and physical well-being were similar between groups (p>0.05). At 3 months postoperatively, the Alloderm group had a statistically significant improvement with respect to satisfaction with breasts (67 vs 53, p = 0.03), satisfaction with overall results (85 vs 61, p = 0.003), satisfaction with the surgeon (89 vs 67, p = 0.01), and satisfaction with information provided (74 vs 59, p = 0.02). At 12 months postoperatively, there were no statistically significant differences in PROM between groups (p>0.05). CONCLUSION: We report the first randomized controlled trial to date comparing patient-reported outcomes of the two most commonly used ADMs in IBR in Canada. Although a short-term analysis favors the use of Alloderm, there does not appear to be any difference in outcomes between the two products in the longer term.
引用
- Stein MJ, Arnaout A, Lichtenstein JB, et al. A comparison of patient-reported outcomes between Alloderm and Dermacell in immediate alloplastic breast reconstruction: A randomized control trial. J Plast Reconstr Aesthet Surg. 2020. PMID: 32893151. doi:10.1016/j.bjps.2020.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。